Printer Friendly

e-Therapeutics names Daniel Elger CFO.

M2 PHARMA-June 13, 2011-e-Therapeutics names Daniel Elger CFO(C)2011 M2 COMMUNICATIONS

13 June 2011 - UK-based e-Therapeutics plc (LON: ETX) said today it has named Dr Daniel Elger chief financial officer and board member.

Dr Elger was previously the VP, Marketing & Communications at cancer drug developer Antisoma plc (LON: ASM). He joined that company in 2002 and served on its senior management team from 2005. He also directed the investor relations strategy for the company.

Prior to Antisoma, Dr Elger was a Programme director for major pharmaceutical companies at a marketing and communications agency. He holds a BA in Physiological Sciences (Medicine) and a PhD in cancer cell biology, both from Oxford University.

The company also announced the departure of J.M. Cordiner from his position as finance director of e-Therapeutics and from the board on 10 June, in order to pursue other business interests.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 13, 2011
Words:156
Previous Article:Valeant, GlaxoSmithKline say FDA greenlights Potiga.
Next Article:FDA okays redesigned labels for certain Merck drugs.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters